Results Release and Webinar Discussion on Morning of December 18, 2025MISSISSAUGA, Ontario, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its fourth quarter of fiscal 2025 ended September 30, 2025 (“Q4 2025”) prior to the start of trading on December 18, 2025. At 10:00 AM ET that d ...

MISSISSAUGA, Ontario, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces the commercial launch of QAPs™ quality assessment products and availability of QUANTDx™ reference materials to support antigen or molecular tests for H3N2 strains of seasonal Influenza A (a.k.a., the “Flu”). H3N2, alongside H1N1, is a common type of Influenza A that circulates annually, with H3N2 more prone to “antigenic drift, ...

For Repurchase of up to 5% of its outstanding shares over 12 monthsMISSISSAUGA, Ontario, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®) (“Microbix” or the “Company”), a life sciences innovator, manufacturer, and exporter, announces the initiation of a Normal Course Issuer Bid (“NCIB”) program for the repurchase and cancellation of outstanding common shares. Specifically, the NCIB enables Microbix to repurchase up to 6,949,346 Common Shares ("Shares"), that num ...

Core Insights - Microbix Biosystems Inc. is addressing a cybersecurity incident involving a ransomware attack that resulted in data theft but did not disrupt operations [1][2][3] - The company has been enhancing its cybersecurity measures since early 2022, including the implementation of advanced software systems [4][8] - Microbix has a policy of not paying ransoms to hackers, aiming to discourage cybercrime [4] Company Overview - Microbix is a life sciences innovator focused on creating proprietary biological products for human health, with over 120 employees and monthly revenues targeting C$ 2.0 million or more [5][6] - The company manufactures critical ingredients for the global diagnostics industry, including antigens for immunoassays and quality assessment products [5] - Microbix's products are sold in over 30 countries and are supported by a network of international distributors [5] Cybersecurity Measures - The company has adopted the Center for Internet Security (CIS) frameworks for its cybersecurity programs [8] - Regular employee cybersecurity training and endpoint server protection for real-time threat monitoring are part of the ongoing improvements [8] - Microbix is also focusing on disaster-recovery and business-continuity planning [8]

Core Insights - Microbix Biosystems Inc. will present to investors at the Muskoka Capital Event from September 26 to 28, 2025, focusing on growth-oriented investors [1][2] - The company aims to engage in 18 one-on-one meetings with investors during the event [2] - Microbix generates revenues targeting C$ 2.0 million or more per month and employs over 120 skilled employees [3] Company Overview - Microbix specializes in proprietary biological products for human health, particularly in the global diagnostics industry [3] - The company produces critical ingredients such as antigens for immunoassays and laboratory quality assessment products (QAPs™) [3] - Microbix's products are sold in over 30 countries, supported by a network of international distributors [3] - The company is ISO 9001 & 13485 accredited and registered with U.S. FDA, Australian TGA, and Health Canada [3] Product Development - Microbix develops proprietary products including Kinlytic® urokinase, a biologic thrombolytic drug, and reagents for molecular diagnostic testing [4] - The company’s QAPs and QUANTDx products support clinical lab accreditation and diagnostic workflows [3][4] Event Information - The Muskoka Capital Event is organized by Capital Event Management Ltd., featuring public and private companies and a range of investors [5] - The event aims to foster relationships that lead to financings and increased awareness within the investment community [5]

Core Insights - Microbix Biosystems Inc. and Labquality Oy have launched a new external quality assessment (EQA) program aimed at improving the accuracy of clinical laboratories in identifying head and neck cancers associated with HPV [1][4] Group 1: Industry Context - Head and neck cancers (HNCs) are increasingly common, particularly in males, with over 300,000 cases diagnosed annually in North America and Western Europe, representing about 4% of all cancers [2] - Accurate identification of HPV-driven HNCs is crucial as these patients have better prognoses, influencing treatment decisions [2] Group 2: EQA Program Details - The EQA program was developed to address the lack of proficiency checks for clinical labs working with FFPE samples, which are used for diagnosing HNCs [3] - Microbix created QAPs™ that mimic HNC patient samples, containing both IHC and PCR targets, to support the EQA program [5] - A pilot study involving 32 clinical laboratories revealed significant discrepancies in p16 IHC staining protocols, highlighting the need for improved diagnostic accuracy through reflex testing [4] Group 3: Company Profiles - Microbix Biosystems Inc. specializes in creating biological products for human health, with revenues targeting C$ 2.0 million or more per month and a focus on the global diagnostics industry [7] - Labquality Oy provides EQA services to over 8,000 customers in more than 60 countries, emphasizing quality in clinical laboratories and point-of-care testing [9]

Core Insights - Microbix Biosystems Inc. will present its H5N1 pandemic preparedness results at the ADLM conference in Chicago from July 28 to 31, 2025 [1][2] - The company will showcase its quality assessment products (QAPs™) that ensure the accuracy of antigen and molecular tests [2][3] - A pilot External Quality Assessment (EQA) program will be presented, focusing on the detection of the H5N1 strain using existing molecular tests [3][4] Company Overview - Microbix is a life sciences innovator with over 120 employees and aims for revenues of C$ 2.0 million or more per month [6] - The company specializes in proprietary biological products for human health, including antigens for immunoassays and QAPs that support clinical lab proficiency testing [6][7] - Microbix's QAPs are available in over 30 countries and are supported by a network of international distributors [6] Product Development - The H5N1 QAPs were developed to ensure full genetic coverage of potential pandemic strains and are available in liquid and FLOQSwab formats [5] - The collaboration with American Proficiency Institute (API) is crucial for evaluating the performance of flu tests in detecting H5N1 [4][5] - The company emphasizes the rapid deployment of its capabilities in response to emerging pandemics [5]

Core Viewpoint - Microbix Biosystems Inc. has entered into a multi-year agreement with the National Center for Infectious and Parasitic Diseases of Bulgaria (NCIPD) to develop new quality assessment products (QAPs™) using pathogen seedstocks supplied exclusively by NCIPD, aiming to enhance the accuracy of diagnostic tests for infectious diseases [1][2]. Company Overview - Microbix Biosystems Inc. is a life sciences innovator with nearly 40 years of experience in producing biological ingredients, particularly QAPs, which are critical for validating diagnostic tests [4][6]. - The company employs over 120 skilled workers and targets sales of C$ 2.0 million or more per month, exporting products to over 30 countries [6][8]. Partnership Details - The agreement with NCIPD includes a license fee, material-transfer fees, and royalties on net sales of related QAPs, allowing Microbix to commercialize multiple new QAPs that will support the accuracy of tests for diagnosing infectious diseases [2][5]. - NCIPD, established in 1881, is recognized as a leading institution in the field of infectious and parasitic diseases and has developed an extensive collection of characterized microorganisms [3][5]. Product Development - Microbix currently offers approximately 300 QAPs and expects to significantly increase this number through the collaboration with NCIPD, which will provide inactivated and stabilized mimetics of patient samples for test validation [4][2]. - The collaboration aims to ensure the accuracy of emerging tests for bacterial, parasitic, and viral infections, thereby improving global health outcomes [2][5].

Core Insights - Microbix Biosystems Inc. reported Q2 and H1 fiscal 2025 results, showing a mixed performance with improved gross margins but a decline in overall revenues compared to the previous year [1][2][6]. Financial Performance - Q2 revenue was $5.3 million, a 5% decrease from $5.6 million in Q2 2024, with antigen revenues increasing by 5% to $4.3 million, while QAPs revenues fell by 38% to $864,320 due to delays in assay-development programs [3][10]. - H1 revenue totaled $11.4 million, a 19% decrease from $14.0 million in H1 2024, influenced by the absence of $4.1 million in Kinlytic licensing payments; excluding this, revenues increased by 14% [6][8]. - Gross margin for Q2 improved to 60% from 53% in the previous year, driven by better manufacturing efficiencies and pricing strategies [4][10]. - H1 gross margin was 61%, slightly down from 65% in H1 2024, but improved by 10% when excluding the impact of Kinlytic licensing revenues [7]. Operating Expenses and Income - Operating expenses in Q2 increased by 21% compared to Q2 2024, primarily due to higher investments in R&D and sales and marketing [4][10]. - Q2 net income was $20,664, a significant drop from $377,730 in Q2 2024, while H1 net income was $877,627 compared to $2.8 million in H1 2024, largely due to the absence of Kinlytic licensing fees [5][8]. Cash Position and Liquidity - Cash and equivalents at the end of Q2 stood at $14.5 million, an increase of $1.5 million from the previous quarter, despite debt repayments and share repurchases [5][10]. - The current ratio improved to 9.68, and the debt to equity ratio decreased to 0.27, indicating enhanced financial strength [9][10]. Business Outlook - Management expressed a cautious outlook for the second half of fiscal 2025, particularly for the Antigens business, due to reduced sales into China [2][11].

Core Insights - Microbix Biosystems Inc. and Aurevia Oy are launching a pilot external quality assessment program to enhance clinical laboratories' proficiency in diagnosing bacterial vaginosis using molecular diagnostic methods [1][3] - The program aims to provide definitive diagnoses for bacterial vaginosis and other vaginal infections, improving treatment plans and patient care [2][5] Company Overview - Microbix Biosystems Inc. specializes in creating proprietary biological products for human health, with a monthly sales target of C$ 2.0 million or more and a workforce of over 120 employees [6] - The company manufactures critical ingredients and devices for the global diagnostics industry, including antigens for immunoassays and laboratory quality assessment products [6][7] - Microbix is ISO 9001 & 13485 accredited and has a presence in over 30 countries through a network of international distributors [6] Industry Context - Bacterial vaginosis is a common condition affecting a significant percentage of women, traditionally diagnosed through less definitive methods [2] - Molecular diagnostic tests offer a more accurate means of diagnosis by distinguishing the organisms present in vaginal flora [2] - The EQA program will utilize simulated samples created by Microbix to emulate clinical specimens, ensuring safe and stable testing conditions [4][3] Program Details - The pilot program, titled "Bacterial vaginosis and vaginitis multiplex nucleic acid detection," will assess clinical labs' capabilities in diagnosing bacterial vaginosis and other vaginal infections [3] - Microbix has developed three quality assessment products (QAPs) specifically for this pilot, designed to emulate the workflow of molecular diagnostic tests [4] - Following the pilot study, an ongoing program for bacterial vaginosis is expected to be integrated into Aurevia's Labquality EQAS portfolio [3] Leadership Commentary - Aurevia's EQA Solutions Manager emphasized the importance of validating emerging molecular diagnostic tests to improve access to care and ensure accurate diagnoses [5] - The CEO of Microbix expressed pride in collaborating with Aurevia to validate next-generation diagnostic tests, aiming to support clinical labs in achieving high levels of accuracy and quality assurance [5]